Quick answer: Tesamorelin can cause injection-site reactions, joint or muscle discomfort, swelling from fluid retention, and changes in blood sugar. Most side effects are not emergencies, but allergic reactions, significant swelling, or concerning changes in glucose need prompt medical attention. Your provider may also monitor IGF-1 and blood sugar during treatment.
What’s Commonly Reported
Common tesamorelin side effects
Based on the pivotal clinical trials, these are the most frequently reported effects:
25% in trials
Injection-site reactions
Redness, itching, pain, irritation, or bruising where the medication is injected.
Commonly reported
Joint discomfort
Joint discomfort can occur along with other fluid-retention symptoms such as swelling or hand and wrist symptoms.
Reported
Peripheral edema
Mild swelling, typically in the hands or feet, related to fluid retention.
What You May Notice
What It Can Mean
What to Do
Redness, itching, pain, or bruising at the injection site
A common injection-site reaction
Rotate injection areas as instructed and contact your provider if the reaction is severe or persistent.
Swelling, joint discomfort, or hand/wrist symptoms
Possible fluid retention
Tell your provider, especially if symptoms are increasing or affecting daily activity.
Changes in blood sugar
Tesamorelin can affect glucose regulation
Follow your provider’s plan for glucose or HbA1c monitoring.
Hives, facial or throat swelling, trouble breathing
Possible serious allergic reaction
Stop treatment and seek emergency medical care.
Less Common
Rare effects worth understanding
Effect
What to Know
Myalgia (muscle aches)
Reported in trials, generally mild and often resolving as treatment continues.
Pain in extremities
Reported alongside joint-related effects, usually manageable.
Increased IGF-1 levels
Expected physiological response to GH stimulation; monitored via bloodwork during treatment.
Numbness or tingling
Rarely reported at the injection site; usually resolves quickly.
“Most patients tolerate tesamorelin well. The joint discomfort some people notice early on tends to ease as the body adjusts — but we watch closely during the first few weeks so nothing goes unaddressed.”
— Dr. Rosemary Daly, D.O.
“I always tell patients the goal isn’t to avoid every possible side effect on a list — it’s to know what’s expected, what’s worth watching, and when to call us. That’s what keeps treatment both safe and manageable.”
— Karla K. Mioduchoski, FNP-BC
Monitoring During Treatment
Blood Sugar and IGF-1 Monitoring
Tesamorelin can raise IGF-1 and may affect blood sugar. That does not mean every patient will develop a problem, but it is one reason medical follow-up matters.
Blood sugar
Your provider may check glucose or HbA1c before treatment and periodically afterward, especially if you already have diabetes or are at risk for it.
IGF-1
Tesamorelin increases IGF-1 as part of its expected biological effect. Providers may use blood tests to make sure levels are not staying excessively elevated.
Why this matters: these labs give your provider another way to judge how your body is responding instead of relying only on how you feel.
Being Thorough
Serious considerations
Because tesamorelin stimulates growth hormone release, there are specific safety considerations your provider will review before prescribing:
Not recommended for patients with active malignancy, given growth hormone’s role in cell growth pathways
Requires caution in patients with diabetes, as GH can affect glucose regulation
Not studied for safety in pregnancy — not appropriate for patients who are pregnant or trying to conceive
Fluid retention effects warrant caution in patients with certain cardiac or kidney conditions
Your provider reviews your complete health history before prescribing tesamorelin specifically because of these considerations. This is not a peptide to source or use without full medical evaluation.
Compounded Formulations
Compounded Tesamorelin Side Effects
Patients using compounded tesamorelin may experience some of the same types of side effects associated with tesamorelin, including injection-site reactions, swelling, joint discomfort, and changes in blood sugar.
Compounded tesamorelin is not FDA-approved, and compounded formulations should not be assumed to have the same clinical-trial evidence as FDA-approved EGRIFTA WR. The concentration, formulation, and dispensing instructions may also differ by pharmacy.
Important: If you are prescribed compounded tesamorelin, follow the exact instructions from your prescribing clinician and dispensing pharmacy. Contact your provider if you develop persistent side effects, unexpected symptoms, or questions about your formulation.
What to Expect
Week-by-week and month-by-month symptom pattern
Early Treatment
Starting Out
Injection-site reactions can occur after treatment begins. Pay attention to redness, itching, pain, irritation, or bruising.
As Treatment Continues
Watch for New Symptoms
Tell your provider about joint discomfort, swelling, numbness, tingling, or other symptoms that are new or getting worse.
Ongoing Treatment
Follow-Up Matters
Your provider can review tolerance, symptoms, blood sugar, and laboratory results as treatment continues.
Longer-Term Care
Continue Monitoring
Ongoing medical follow-up may include IGF-1 and glucose monitoring based on your health history and treatment plan.
Tesamorelin side effects may change over time. This educational timeline highlights symptoms to monitor and warning signs that should be discussed with your healthcare provider.
Know the Warning Signs
When to contact your provider
Signs of a significant allergic reaction — swelling of the face or throat, difficulty breathing, or hives
Severe or worsening joint pain that limits daily activity
Significant swelling in the hands, feet, or legs
Any symptom that feels significantly different from what you were told to expect
If you experience signs of a serious allergic reaction or any medical emergency, call 911 or go to the nearest emergency room. For non-emergency concerns, contact your GoalBMI Wellness provider directly.
Answers
Frequently asked questions about tesamorelin side effects
Injection-site reactions are common. Current EGRIFTA WR prescribing information reports them in 25% of tesamorelin-treated patients versus 14% of placebo-treated patients during the first 26 weeks. Reactions can include redness, itching, pain, irritation, or bruising.
Joint discomfort has been reported with tesamorelin and can occur as part of fluid-retention effects. Contact your provider if pain is significant, persistent, or accompanied by swelling or hand/wrist symptoms.
Long-term treatment should be supervised by a healthcare provider. Monitoring may include symptoms, IGF-1 levels, and glucose status depending on your health history and treatment plan.
Tesamorelin is not recommended for patients with active malignancy, and requires careful consideration in patients with diabetes or certain cardiac and kidney conditions due to fluid retention effects. It has not been studied for safety in pregnancy.
Mild redness or swelling often resolves on its own. Rotating injection sites and following proper technique helps reduce recurrence. See our injection guide for step-by-step technique, and contact your provider if reactions are severe or persistent.
Side effects may overlap, but compounded tesamorelin products are not FDA-approved and have not been evaluated through the same approval process as EGRIFTA WR. Ask your provider about the specific formulation, concentration, and monitoring plan prescribed for you.
This page uses current prescribing information for EGRIFTA WR (tesamorelin) for adverse reactions, contraindications, glucose monitoring, IGF-1 monitoring, fluid retention, hypersensitivity, and injection-site reactions.
Written by Karla K. Mioduchoski, FNP-BC — GoalBMI Wellness
This page was written by Karla K. Mioduchoski, FNP-BC and medically reviewed by Dr. Rosemary Daly, D.O., providing physician-supervised peptide therapy, medical weight loss, and telehealth wellness care through GoalBMI Wellness, serving patients across New York.
⚠️ Medical & Educational Disclaimer: Tesamorelin (brand names Egrifta® / Egrifta WR®) is FDA-approved specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Use for general visceral fat or metabolic wellness goals outside this approved indication is off-label and is determined individually by a licensed provider following evaluation. Nothing on this page is a promise of specific results. Always follow the exact instructions of your prescribing provider. Peptide therapy is available only to eligible patients in states where our providers are licensed. In a medical emergency, call 911.
Get Started
Book an appointment and take the first step toward better health.
